Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision number changed from v3.7.1 to v3.7.2; the study page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T15:26:35.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T15:17:48.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record details. This replaces the trial information with an access-denied screen.
    Difference
    22%
    Check dated 2026-09-20T20:35:07.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Revision metadata on the page was updated from v3.6.5 to v3.6.6, indicating a minor version update to the page’s backend or documentation. This change does not modify the study content or data presented on the page.
    Difference
    0.0%
    Check dated 2026-08-30T22:01:23.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The page revision label was updated to v3.6.5, indicating a new site build rather than changes to the study details.
    Difference
    0.0%
    Check dated 2026-08-09T09:13:08.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    IPD (Individual Participant Data) data-sharing plan added and related terminology updated. Study Protocol and Statistical Analysis Plan are now linked, and MeSH terms and record history metadata expanded to improve indexing and transparency of the trial record.
    Difference
    78%
    Check dated 2026-08-01T20:33:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.